ATE219495T1 - Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel - Google Patents

Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel

Info

Publication number
ATE219495T1
ATE219495T1 AT96937702T AT96937702T ATE219495T1 AT E219495 T1 ATE219495 T1 AT E219495T1 AT 96937702 T AT96937702 T AT 96937702T AT 96937702 T AT96937702 T AT 96937702T AT E219495 T1 ATE219495 T1 AT E219495T1
Authority
AT
Austria
Prior art keywords
hypocholesterdenic
azetidinone
drugs
usable
sugar substituted
Prior art date
Application number
AT96937702T
Other languages
English (en)
Inventor
Nathan P Yumibe
Kevin B Alton
Heek Margaret Van
Harry R Davis
Wayne D Vaccaro
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26677904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE219495(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE219495T1 publication Critical patent/ATE219495T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT96937702T 1995-10-31 1996-10-29 Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel ATE219495T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US818595P 1995-10-31 1995-10-31
US57084795A 1995-12-12 1995-12-12
PCT/US1996/016823 WO1997016455A1 (en) 1995-10-31 1996-10-29 Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents

Publications (1)

Publication Number Publication Date
ATE219495T1 true ATE219495T1 (de) 2002-07-15

Family

ID=26677904

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96937702T ATE219495T1 (de) 1995-10-31 1996-10-29 Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel

Country Status (28)

Country Link
EP (1) EP0877750B1 (de)
JP (2) JP3385031B2 (de)
KR (1) KR100311554B1 (de)
CN (1) CN1103780C (de)
AR (1) AR004701A1 (de)
AT (1) ATE219495T1 (de)
AU (1) AU712158B2 (de)
BR (2) BR9611401B1 (de)
CA (1) CA2235943C (de)
CY (1) CY2353B1 (de)
CZ (1) CZ293957B6 (de)
DE (1) DE69621952T2 (de)
DK (1) DK0877750T3 (de)
ES (1) ES2175141T3 (de)
GE (1) GEP20033006B (de)
HK (1) HK1012507A1 (de)
HU (1) HU226822B1 (de)
ID (1) ID16177A (de)
IL (1) IL124268A (de)
MX (1) MX9803447A (de)
MY (1) MY114803A (de)
NO (1) NO311692B1 (de)
NZ (1) NZ321766A (de)
PL (1) PL184698B1 (de)
PT (1) PT877750E (de)
SK (1) SK283552B6 (de)
TW (1) TW448181B (de)
WO (1) WO1997016455A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
EP1510521A1 (de) * 2000-12-20 2005-03-02 Schering Corporation Zuckersubstituierte 2-Azetidinone Verwendbar als Hypocholesterdenische Arzneimittel
CA2432798C (en) * 2000-12-20 2007-02-27 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU2002216097B2 (en) 2000-12-21 2006-09-07 Sanofi-Aventis Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
RU2314126C2 (ru) * 2001-01-26 2008-01-10 Шеринг Корпорейшн Комбинации ингибитора (ингибиторов) всасывания стерина с модификатором (модификаторами) крови, предназначенные для лечения патологических состояний сосудов
CZ305202B6 (cs) * 2001-01-26 2015-06-10 Merck Sharp & Dohme Corp. Farmaceutický prostředek
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
CA2442219C (en) 2001-03-28 2007-09-11 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
AU2002336609B2 (en) * 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1522541A1 (de) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Neue hypocholesterolemische Verbindungen
AU2004286838A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
AU2004303742B2 (en) 2003-12-23 2008-06-19 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1877067A1 (de) * 2005-04-26 2008-01-16 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-on-glucuronid-derivate gegen hypercholesterinämie
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AU2006304836A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
CN103102297A (zh) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 一种新的依折麦布的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
CA2120221A1 (en) * 1993-04-23 1994-10-24 Allan W. Rey N-substituted 2-azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
TW448181B (en) 2001-08-01
CZ129498A3 (cs) 1998-10-14
NZ321766A (en) 1999-07-29
NO981950D0 (no) 1998-04-29
PL327987A1 (en) 1999-01-04
MY114803A (en) 2003-01-31
CN1205707A (zh) 1999-01-20
CA2235943A1 (en) 1997-05-09
KR100311554B1 (ko) 2002-06-20
CY2353B1 (en) 2004-06-04
NO981950L (no) 1998-06-26
SK283552B6 (sk) 2003-09-11
SK48398A3 (en) 1998-11-04
BR9612998B1 (pt) 2010-03-23
CA2235943C (en) 2002-10-01
HK1012507A1 (en) 1999-08-06
ES2175141T3 (es) 2002-11-16
CZ293957B6 (cs) 2004-08-18
ID16177A (id) 1997-09-11
JPH10512592A (ja) 1998-12-02
CN1103780C (zh) 2003-03-26
KR19990067202A (ko) 1999-08-16
AR004701A1 (es) 1999-03-10
DE69621952T2 (de) 2003-01-16
MX9803447A (es) 1998-09-30
IL124268A (en) 2005-08-31
WO1997016455A1 (en) 1997-05-09
HUP9802539A2 (hu) 1998-11-30
HUP9802539A3 (en) 1999-12-28
AU7517996A (en) 1997-05-22
GEP20033006B (en) 2003-07-10
HU226822B1 (en) 2009-11-30
EP0877750B1 (de) 2002-06-19
AU712158B2 (en) 1999-10-28
JP2001048895A (ja) 2001-02-20
DE69621952D1 (de) 2002-07-25
JP3385031B2 (ja) 2003-03-10
BR9611401A (pt) 1999-01-05
DK0877750T3 (da) 2002-07-15
PT877750E (pt) 2002-09-30
NO311692B1 (no) 2002-01-07
EP0877750A1 (de) 1998-11-18
PL184698B1 (pl) 2002-12-31
BR9611401B1 (pt) 2010-08-10

Similar Documents

Publication Publication Date Title
ATE219495T1 (de) Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
DE69629755D1 (de) Irbesartanhaltiges Arzneimittel
DE69713284D1 (de) Triazol-Derivate als Arzneimittel
NL300214I2 (nl) Chinazolinederivaten.
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
IS1903B (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
DE69737936D1 (de) Arzneimittel
FI950715A0 (fi) Ytmikromekanisk, symmetrisk tryckskillnadsgivare
TR199600883A2 (tr) Pürin-6-on türevleri.
DE60106489D1 (de) Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
TR199600715A2 (tr) Kefalosforin türevleri.
NO960499D0 (no) Antineurodegenerativt virksomme 10-aminoalifatyldibenz[b,fÅoksepiner
DE69628458D1 (de) 25-hydroxy-16-ene-26,27-bishome-cholecalceriferol derivate
TR199601012A2 (tr) Sampuan terkibi.
TR199600064A2 (tr) 4-amino-benzoilguanidin-türevleri.
TR199601018A1 (tr) Farmasötik bilesikler.
ES1032571Y (es) Gafa,
NL1000212C2 (nl) Scharniersysteem.
IT1276501B1 (it) Via tranviaria.
TR199600311A1 (tr) Pelit sekeri.
ES1030601Y (es) Radiador-convector, perfeccionado.
ES1032115Y (es) Bisagra.
FI953158A0 (fi) Foerfarande foer biologisk rening av vatten, saerskilt foer minskning av kvaevehalten
ES1031395Y (es) Minicapsula de maquillaje.
ES1035918Y (es) Bolsa de azucar.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification